Lord, Abbett & Co
CBAY

Lord, Abbett & Co’s Cymabay Therapeutics CBAY Stock Holding History

Lord, Abbett & Co’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,321,219
Closed -$31.2M – 600
2023
Q4 		$31.2M Buy
+1,321,219
New +$23.5M 0.11% 250

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Lord, Abbett & Co's CBAY Position: Q1 2024 in Review

Lord, Abbett & Co sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 1,321,219 shares — an estimated $31.2M sold.

Lord, Abbett & Co first reported a position in CBAY in Q4 2023 and held it in 1 quarter. The position peaked at $31.2M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Lord, Abbett & Co reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Lord, Abbett & Co sold 1,321,219 Cymabay Therapeutics shares in Q1 2024, an estimated $31.2M.
  • Lord, Abbett & Co first reported a position in Cymabay Therapeutics in Q4 2023 and held it in 1 quarter.
  • Lord, Abbett & Co's Cymabay Therapeutics position peaked at $31.2M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Lord, Abbett & Co's 13F filing for Q1 2024, filed 9 May 2024.